VENTURA, Calif. (CN) - A grandfather claims in court that his 5-year-old grandson is developing secondary sexual characteristics because grandpa's pharmacist failed to warn that his prescribed testosterone could be transmitted to the boy.
Nabil Sakla sued pharmacist Robert Blomquist and Cabrillo Pharmacy in Superior Court, on behalf of Sakla's grandson.
Sakla's attorney declined to discuss the case because of its sensitive nature.
"Because my client is a young boy, I'm really uncomfortable talking about it in these circumstances," David Reinard of Seal Beach told Courthouse News in an interview.
According to the complaint, Sakla's doctor prescribed him testosterone in 2009 to treat a "medical condition," which the complaint does not identify. Sakla says he filled his prescription only at the Cabrillo Pharmacy.
Sakla and his wife were raising their young grandson.
"In the process of caring for and raising (the boy), Nabil Sakla came into physical contact with (him) on a regular basis, as was reasonably foreseeable," the complaint states.
"In 2011, while (the boy) was at a doctor's appointment, (his) physician noted that (the boy), at the time only 5 years old, was developing secondary sexual characteristics, which were not expected to occur for many years.
"It was determined that (the boy's) condition was as a result of exposure to the testosterone which had been supplied to Nabil Sakla by Robert Blomquist, Cabrillo Pharmacy, and does 1 to 10."
Sakla claims the defendants never told him the testosterone could be transmitted to other people, and failed to warn him about the health risks to minors exposed to testosterone.
Had he known, Sakla says, he would have "acted so as to eliminate any risk of harm to (his grandson), as he did after he was informed that the testosterone was responsible for harm to (the boy)."
Sakla claims his grandson has experienced "serious bodily injury" and "will incur medical and related expenses" because of his exposure to the testosterone.
He seeks damages for negligence, and medical expenses.
Subscribe to Closing Arguments
Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.